Properties of commercial factor IX concentrates.
D000818:Animals; D000990:Antithrombin III; D001777:Blood Coagulation; D005591:Chemical Fractionation; D003132:Commerce; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D004285:Dogs; D005164:Factor IX / Q000502:physiology / Q000592:standards / Q000627:therapeutic use*; D015949:Factor IXa; D005169:Factor VIII; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000473:pathology; D051379:Mice; D009336:Necrosis; D010314:Partial Thromboplastin Time; D011817:Rabbits; D013927:Thrombosis / Q000209:etiology; D000511:alpha-Macroglobulins
D000511:alpha-Macroglobulins; D000990:Antithrombin III; D005169:Factor VIII; D005164:Factor IX; D015949:Factor IXa